Bedminster, NJ - According to Eric Strauss of NJBiz, "Biopharmaceutical company Matinas BioPharma Holdings Inc. has named a former Rutgers University professor as its new senior vice president and chief technology officer, it announced Tuesday. Raphael J. Mannino spent 25 years as a professor of pathology and laboratory medicine at the Rutgers University, New Jersey Medical School. He joined Matinas’ scientific advisory board in January.
Matinas focuses on antifungal and antibacterial therapeutics for treatment of infections.
“I am very pleased to be joining the Matinas BioPharma team to lead the company’s initiatives as we work to advance our orally administered, encochleated broad-spectrum fungicidal and broad-spectrum aminoglycoside antibiotic drug formulations from clinical development toward commercialization to help treat patients with serious and life-threatening infections,” Mannino said in a prepared statement.
The company said Mannino’s field of expertise is artificial lipid-based structures for the formulation and delivery of biologicals and pharmaceuticals. He is a pioneer in the use of cochleate technology for these purposes, the company added.
“We have been working very closely with Dr. Mannino as a scientific adviser, and we are honored to officially welcome him as a member of our management team,” Roelof Rongen, CEO and president, said in a statement.
For the full story:
http://www.njbiz.com/article/20150901/NJBIZ01/150909988/biopharma-company-names-former-rutgers-professor-to-its-management-team?utm_source=Listrak&utm_medium=Email&utm_term=http%3a%2f%2fwww.njbiz.com%2farticle%2f20150901%2fNJBIZ01%2f150909988%2fbiopharma-company-names-former-rutgers-professor-to-its-management-team&utm_campaign=The+Daily%3a+Biopharma+company+names+former+Rutgers+professor+to+its+management+team%2c+Vonage+wraps+up+
“I am very pleased to be joining the Matinas BioPharma team to lead the company’s initiatives as we work to advance our orally administered, encochleated broad-spectrum fungicidal and broad-spectrum aminoglycoside antibiotic drug formulations from clinical development toward commercialization to help treat patients with serious and life-threatening infections,” Mannino said in a prepared statement.
The company said Mannino’s field of expertise is artificial lipid-based structures for the formulation and delivery of biologicals and pharmaceuticals. He is a pioneer in the use of cochleate technology for these purposes, the company added.
“We have been working very closely with Dr. Mannino as a scientific adviser, and we are honored to officially welcome him as a member of our management team,” Roelof Rongen, CEO and president, said in a statement.
For the full story:
http://www.njbiz.com/article/20150901/NJBIZ01/150909988/biopharma-company-names-former-rutgers-professor-to-its-management-team?utm_source=Listrak&utm_medium=Email&utm_term=http%3a%2f%2fwww.njbiz.com%2farticle%2f20150901%2fNJBIZ01%2f150909988%2fbiopharma-company-names-former-rutgers-professor-to-its-management-team&utm_campaign=The+Daily%3a+Biopharma+company+names+former+Rutgers+professor+to+its+management+team%2c+Vonage+wraps+up+
